A randomized, multicenter, double-blind, placebo-controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma Multiforme-the Immunesense Study (Brain Tumors)
Sponsor: |
Imvax |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT5656 |
U.S. Govt. ID: |
NCT04485949 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to see how safe the study medicine, IGV-001 plus standard of care (SOC), is and to compare IGV-001 with placebo to see if it works in slowing glioblastoma multiforme (GBM) tumor regrowth. SOC refers to the usual medicine(s) or procedures used to treat your cancer. A placebo looks like the study medicine but does not contain any medication (active ingredient). Researchers use a placebo to see if a study medicine works better or is safer than not taking anything at all.
This study is closed
Investigator
Fabio Iwamoto, MD
Are you 18 to 70 years old? |
Yes |
No |
Have you been diagnosed with a brain tumor called glioblastoma multiforme (GBM)? |
Yes |
No |